Jefferies Global Healthcare Conference
Logotype for Autolus Therapeutics plc

Autolus Therapeutics (AUTL) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Autolus Therapeutics plc

Jefferies Global Healthcare Conference summary

17 Nov, 2026

Commercial performance and adoption

  • AUCATZYL (obe-cel) generated $74M in its first launch year; second-year revenue reached $113M in the first 9 months, including $41M in Q3. FY guidance rose from $120M-$135M to $140M-$150M; revenue is now expected at $150M or higher.

  • The U.S. launch has reached 90 centers and the U.K. 20; second-year revenue is expected to increase ~100% YoY, supported by physician experience and peer communication.

  • U.S. coverage exceeds 80% of patients; expansion will target geographic gaps, referring centers with patient flow, and facilities where CAR T-trained physicians establish practices.

  • ROCCA real-world data covering about two-thirds of first-year patients showed no high-grade cytokine release syndrome, 3% higher-grade transient neurological toxicity, and clinical activity above 90%.

  • Adoption is expected to build gradually as physicians gain confidence and use obe-cel across more eligible patients; conference presentations and peer exchange are key potential catalysts.

Manufacturing and margins

  • Q3 gross margin was 57%; year-to-date gross margin was 44%. Production is expected to double versus last year with fewer manufacturing operators and staff.

  • Gross margin is targeted at 65%-70% by 2028, with the ALL business expected to be cash-flow positive in 2028.

  • Margin improvement is expected from higher production volume spreading fixed costs and continued operational efficiency work across manufacturing steps.

Label and market expansion

  • The pediatric pivotal study is expected to complete enrollment by year-end or very early next year; data are expected at ASH next year, with an sBLA filing ready around that time.

  • Investigator-led frontline studies use two induction chemotherapy cycles followed by obe-cel consolidation, aiming to shorten treatment from 18-36 months to 4-6 months; first MD Anderson data are expected late next year.

  • Discussions are underway with cooperative groups and the NCI on a potential randomized, label-enabling frontline study.

  • The U.S. adult relapsed/refractory ALL peak-sales opportunity is estimated at $500M; expansion across ages and treatment lines could exceed $1B.

  • The U.K. launched in early 2026 after NICE assessment and routine commissioning; sales are expected to reach roughly 10% of U.S. sales. European launches may begin around 2028 if reimbursement and cost of goods support attractive economics; Europe potential was estimated at 20%-25%.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Autolus Therapeutics